Clinical Trial Update: Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered To Infants In Korea [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a 13-valent pneumococcal conjugate vaccine in infants in Korea has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Pneumococcal Vaccine | Phase 2 | Status: COMPLETED | Results posted: 2011-01-11